Given its likely role in the immunopathogenesis of cancer, the anti-LAG-3 antibody relatlimab has also recently received approval for metastatic melanoma, and clinical trials investigating relatlimab in conjunction with other ICIs in various cancers are currently underway [34]. The gene discussed is LAG3; the disease is cancer.